Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CFO Ryan D. Maynard sold 100,000 shares of the firm’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $3.90, for a total value of $390,000.00. Following the sale, the chief financial officer now directly owns 100,000 shares of the company’s stock, valued at approximately $390,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Rigel Pharmaceuticals, Inc. (RIGL) opened at $3.74 on Friday. Rigel Pharmaceuticals, Inc. has a twelve month low of $1.94 and a twelve month high of $4.33.

Rigel Pharmaceuticals (NASDAQ:RIGL) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. The company had revenue of $0.90 million for the quarter. Rigel Pharmaceuticals had a negative return on equity of 102.26% and a negative net margin of 354.14%. The business’s revenue for the quarter was down 76.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.24) earnings per share. research analysts anticipate that Rigel Pharmaceuticals, Inc. will post -0.59 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/rigel-pharmaceuticals-inc-rigl-cfo-sells-390000-00-in-stock/1693171.html.

RIGL has been the subject of several research reports. BMO Capital Markets reaffirmed a “buy” rating and set a $5.00 price target on shares of Rigel Pharmaceuticals in a report on Monday, October 2nd. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Rigel Pharmaceuticals in a report on Monday. Jefferies Group LLC reaffirmed a “buy” rating and issued a $5.00 price target on shares of Rigel Pharmaceuticals in a research note on Wednesday, October 4th. Zacks Investment Research upgraded Rigel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. Finally, ValuEngine cut Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $5.67.

Large investors have recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC grew its holdings in shares of Rigel Pharmaceuticals by 11.3% during the first quarter. Parametric Portfolio Associates LLC now owns 30,815 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 3,118 shares during the last quarter. AXA bought a new stake in shares of Rigel Pharmaceuticals during the second quarter worth about $122,000. Voya Investment Management LLC grew its holdings in shares of Rigel Pharmaceuticals by 30.4% during the second quarter. Voya Investment Management LLC now owns 53,661 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 12,500 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Rigel Pharmaceuticals by 415.2% during the third quarter. SG Americas Securities LLC now owns 59,401 shares of the biotechnology company’s stock worth $151,000 after purchasing an additional 47,872 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new stake in shares of Rigel Pharmaceuticals during the second quarter worth about $193,000. Institutional investors own 76.29% of the company’s stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.